
The public phase of the federal 7-OH scheduling decision is over. The extended comment window on the government’s proposed threshold for 7-hydroxymitragynine closed on September 10, 2026, and nothing has been published since. For the first time in ten weeks, there is no deadline to organize around, no docket to file into and no hearing on the calendar — only a very large administrative record sitting in Washington waiting to be read.
That quiet is not nothing happening. The 7-OH scheduling decision has moved from the agency that proposed it to the office that signs it, and the next thing kratom consumers hear about concentrated 7-OH will most likely be an order rather than an invitation to comment.
📁 What actually closed on September 10
The docket that shut was HHS-OASH-2026-0232, opened by the Office of the Assistant Secretary for Health after the Drug Enforcement Administration filed two notices of intent on July 1, 2026. One notice covered three synthetic and semi-synthetic compounds. The other — the one that drew the crowd — asked what concentration of 7-OH should trigger temporary Schedule I placement.
The agency floated 0.05% 7-OH by weight or volume, which works out to roughly 1 milligram in a tablet, gummy or shot. Essentially every concentrated 7-OH product on the American market today sits far above that line; many are marketed at dosages an order of magnitude higher.
The first 30-day window closed July 31 with more than 32,000 comments on the record. After 7-HOPE Alliance, Doctors for Drug Policy Reform and others asked for more time to answer what they called highly technical scientific questions, OASH reopened the window for 15 additional days. Thousands more filings arrived before it closed on September 10 — a deadline we covered as it approached.
One limit shaped what was usefully submitted. Assistant Secretary for Health Brian Christine wrote that OASH was not soliciting comment on any permanent scheduling decision, on the general safety or utility of kratom products, or on policy questions outside the threshold determination. Comments arguing the broader case for kratom arrived in large numbers, but the question formally on the table was narrow: what number, and why.
⚖️ Why the Attorney General owns the 7-OH scheduling decision
This is the part most coverage skips, and it explains the current silence. Under the Controlled Substances Act, temporary scheduling authority belongs to the Attorney General, who has delegated day-to-day exercise of it to the DEA Administrator. The Secretary of Health and Human Services does not veto the decision; HHS forwards the public record for the Attorney General’s consideration. Christine said as much in the extension notice: comments “will be provided by the Secretary for Health and Human Services for consideration by the Attorney General.”
So the 7-OH scheduling decision now rests with Todd Blanche, sworn in as the 88th Attorney General on August 10, 2026, and with DEA Administrator Terrance Cole. A temporary order takes effect the day it publishes in the Federal Register — no phase-in, no grace period — and runs two years, with a possible one-year extension while permanent scheduling is considered.
“They could have a 7-OH ban right now. I think it more likely, given that the Assistant Secretary for Health has requested the 15-day extension, that they’ll give it time to be evaluated.” — Mac Haddow, American Kratom Association
Haddow’s estimate in late August was roughly a month before an order surfaced. That window is now open. Nobody outside the Justice Department knows the date, and any vendor or advocacy account claiming to know one is guessing.
🌿 The leaf–concentrate line is still holding

The single most consequential feature of the proposal is the one that has survived every revision so far: a threshold, by design, is not a ban on the plant. Botanical kratom leaf containing naturally occurring 7-OH below the specified concentration falls outside the proposed order. DEA has said the temporary scheduling recommendation is not intended to capture the leaf.
That distinction is doing real work, and it is also where the litigation risk lives. When DEA went ahead with temporary Schedule I placement of mitragynine pseudoindoxyl, MGM-15 and MGM-16 in late August, the order’s language about compounds “regardless of numerical designation of atomic positions” raised a question nobody had a clean answer to: what happens when modern testing finds trace amounts of a scheduled compound in ordinary leaf? The American Kratom Association sued DOJ and DEA on September 2 asking a federal court to confirm the answer is nothing — that the order does not reach botanical product on the strength of incidental trace detection. The suit does not ask the court to undo the scheduling of the concentrates themselves.
If the 7-OH order answers that drafting question cleanly, its practical effect is narrow and predictable. If it does not, retailers, labs and state enforcement agencies will spend two years arguing about it.
🏛️ States did not wait, and that turned out to matter
While the federal record was open, statehouses kept moving — and mostly in the direction of regulating rather than prohibiting. North Dakota, which had been under an executive-order ban since early August, replaced it with HB 1628 on September 4: synthetic derivatives and concentrated 7-OH banned, natural leaf legal at 21 and older, lab-verified labeling and retail licensing required. A total-ban bill failed in the House the same day by a single vote. Retail sales there stay paused until administrative rules are written.
Delaware followed on September 8, enacting a Kratom Consumer Protection Act chapter that bars sales to anyone under 21 and orders a report on testing capability and retail licensing by January 1, 2027. Twenty jurisdictions on our state legality map now sit in the regulated column.
Those frameworks matter more than usual right now, because a federal threshold order polices concentration, not labeling, age or testing. A state that already requires lab verification and an age gate has infrastructure a federal order can plug into. A state with nothing has a rule and no way to check it. Consumers comparing labeling and testing practices can start with our kratom vendors directory.
🧭 What to watch next
Three things, in order of likelihood. First, publication of a temporary scheduling order for 7-OH above a threshold — the number itself is what to read, since 0.05% was a proposal, not a commitment. Second, any ruling or agreed language in the AKA’s D.C. district court case, which could settle the trace-detection question before the 7-OH order lands rather than after. Third, the start of permanent scheduling proceedings, which would reopen the broader scientific questions OASH explicitly kept off the table this round.
What is not coming is another comment period on this question. The participation phase of the 7-OH scheduling decision is finished, and the tens of thousands of filings on the docket are the record the Attorney General will be working from.
On safety: kratom and its concentrated derivatives can cause physical dependence, and withdrawal is real — concentrated 7-OH products carry a substantially higher dependence risk than traditional leaf preparations. U.S. poison center calls involving kratom in 2026 have already passed the 2025 annual total. Anyone using kratom daily, in high doses, alongside opioids or other sedatives, or while pregnant should talk to a clinician before changing their use, and should not stop abruptly without guidance.
❓ Frequently asked questions
Is 7-OH banned nationwide right now?
No. As of September 19, 2026 no federal order restricting concentrated 7-OH above a threshold has been published. Three related compounds — mitragynine pseudoindoxyl, MGM-15 and MGM-16 — were placed in temporary Schedule I in late August 2026. Several states and dozens of cities and counties have their own 7-OH restrictions.
Would a federal 7-OH order make kratom leaf illegal?
As proposed, no. The threshold approach targets products above a set 7-OH concentration and is not intended to capture botanical leaf containing naturally occurring trace amounts. Whether the final drafting achieves that cleanly is the open question the American Kratom Association’s September 2 lawsuit is trying to settle for the earlier order.
Who makes the final 7-OH scheduling decision?
The Attorney General holds temporary scheduling authority under the Controlled Substances Act, exercised through the DEA Administrator. HHS forwards the public comment record for consideration; it does not decide. Todd Blanche is the current Attorney General and Terrance Cole is the DEA Administrator.
Can I still submit a comment?
Not to this docket. The extended comment period on HHS-OASH-2026-0232 closed September 10, 2026. Any later permanent scheduling proceeding would open a new record with its own comment period.
How long would a temporary order last?
A temporary scheduling order takes effect on the day it publishes in the Federal Register and remains in force for two years, with a possible one-year extension while permanent scheduling is evaluated.
🔗 Sources
- Federal Register — Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I; Request for Information (July 6, 2026)
- Federal Register — Extension of Comment Period (Aug. 26, 2026)
- Regulations.gov — Docket HHS-OASH-2026-0232
- DEA — Notice of intent to temporarily schedule 7-OH and related substances (July 1, 2026)
- Congressional Research Service — Temporary Control of 7-OH and Related Substances Under the CSA
- Pain News Network — Extension of Comment Period Buys 7-OH Advocates More Time
- U.S. Department of Justice — Office of the Attorney General
- Office of the Governor of North Dakota — HB 1628 signing (Sept. 4, 2026)
- Delaware General Assembly — HB 332 bill detail
Not medical advice. kratom.news reports on kratom law, policy and science for general information only. Nothing here diagnoses, treats or recommends treatment for any condition. Kratom can cause physical dependence and withdrawal. Consult a qualified healthcare professional before starting, changing or stopping any kratom use, especially if you are pregnant, taking other medications or managing a substance use disorder.
